Capricor Therapeutics Faces Class Action Over Deramiocel Misleading Claims and Investor Losses

Capricor Therapeutics Faces Class Action Lawsuit Over Deramiocel Claims

Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit initiated by law firm Levi & Korsinsky, LLP, on behalf of investors. The lawsuit alleges securities fraud stemming from misleading statements made by the company regarding its lead cell therapy candidate, deramiocel, which targets cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The claims focus on a period from October 9, 2024, to July 10, 2025, during which Capricor purportedly exaggerated its ability to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). The lawsuit contends that important adverse information regarding the safety and efficacy data from the Phase 2 HOPE-2 trial was not disclosed, potentially misleading investors regarding the viability of Capricor's therapeutic prospects.

The crux of the allegations lies in the company's communication about the clinical performance of deramiocel. Capricor maintained a positive outlook, suggesting that it was on track to gain FDA approval. However, this assertion came under scrutiny following the FDA's issuance of a Complete Response Letter (CRL) on July 11, 2025, which rejected Capricor’s BLA submission due to a lack of sufficient evidence demonstrating the drug's effectiveness. The company's failure to disclose significant safety concerns and the need for additional clinical data led to a rapid decline in investor confidence, as evidenced by a sharp drop in stock price from $11.40 to $7.64 in a single day.

Investors who experienced financial losses during the specified timeframe have until September 15, 2025, to seek appointment as lead plaintiff in the class action. Notably, participation in the lawsuit does not require individuals to assume any financial risk or obligation, as it is structured to incur no costs for class members. Levi & Korsinsky, known for its success in securities litigation, assures potential participants of its commitment to securing justice for shareholders, having successfully recovered significant amounts in past cases. Interested investors are encouraged to reach out to the firm for further information on the proceedings.

In light of these developments, Capricor Therapeutics faces an uphill battle to restore investor trust and credibility in its clinical programs. The outcome of the class action lawsuit may not only impact the company's financial standing but also its future endeavors in the competitive biotech landscape. As the legal proceedings unfold, the industry watches closely, given the increasing scrutiny surrounding therapeutic claims and regulatory compliance in the biotech sector.